# OnCo record yl201 (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/yl201/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "yl201" ;
  schema:name "YL201"@en ;
  schema:alternateName "Tam-Peli"@en, "Tambotatug Pelitecan"@en ;
  schema:description "YL201 is an experimental antibody-drug conjugate from MediLink Therapeutics (Suzhou) in phase 3 trials for nasopharyngeal carcinoma, non-small-cell lung cancer and small-cell lung cancer, aimed at B7-H3."@en ;
  schema:url <https://onco.cc/drugs/yl201/> ;
  schema:dateModified "2026-09-11"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/search?intr=YL201> ;
  onco:status "phase-3" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:modality "ADC" ;
  onco:cancers <https://onco.cc/cancers/nasopharyngeal/>, <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/sclc/>, <https://onco.cc/cancers/prostate/> ;
  onco:targets <https://onco.cc/targets/b7h3/> ;
  onco:companies <https://onco.cc/companies/medilink/> ;
  onco:trials <https://onco.cc/trials/taishan-301/>, <https://onco.cc/trials/nct06612151/>, <https://onco.cc/trials/nct07739758/>, <https://onco.cc/trials/nct07258979/>, <https://onco.cc/trials/nct07208773/>, <https://onco.cc/trials/nct06241846/>, <https://onco.cc/trials/nct05434234/>, <https://onco.cc/trials/nct07407933/>, <https://onco.cc/trials/nct06057922/> .